Last reviewed · How we verify

Moderna mRNA-1273.222

COVID-19 Prevention Network · Phase 2 active Biologic

Moderna mRNA-1273.222 is a Biologic drug developed by COVID-19 Prevention Network. It is currently in Phase 2 development.

At a glance

Generic nameModerna mRNA-1273.222
SponsorCOVID-19 Prevention Network
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moderna mRNA-1273.222

What is Moderna mRNA-1273.222?

Moderna mRNA-1273.222 is a Biologic drug developed by COVID-19 Prevention Network.

Who makes Moderna mRNA-1273.222?

Moderna mRNA-1273.222 is developed by COVID-19 Prevention Network (see full COVID-19 Prevention Network pipeline at /company/covid-19-prevention-network).

What development phase is Moderna mRNA-1273.222 in?

Moderna mRNA-1273.222 is in Phase 2.

Related